跳至主要内容
临床试验/NCT03380650
NCT03380650Unknown不适用

Study of Combined Use of Directional Atherectomy and Local Drug Delivery With Balloon Catheter System in the Treatment of Femoropopliteal Occlusive Disease

RenJi Hospital0 个研究点目标入组 40 人开始时间: 2018年1月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
40
主要终点
patency rate

研究概览

简要总结

This study will evaluate the effectiveness and safety of directional atherectomy plus local drug delivery using balloon catheter system in the treatment of femoropopliteal occlusive disease. Patients of femoropopliteal occlusive disease will randomly receive directional atherectomy plus local drug delivery using balloon catheter system and dilation using drug-coated balloon. Their clinical outcomes (e.g. 12-month late lumen loss rate, 1-year patency rate of target vessel) in 1 year after the treatment will be compared.

详细描述

Femoropopliteal occlusive disease is a common type of peripheral arterial disease. Endovascular treatment has been the first-line treatment of femoropopliteal occlusive disease. However, the in-stent re-stenosis has been a major limitation of well long-term patency rate after stent implantation. The chronic inflammation induced by stenting could be a main reason of re-stenosis. Then the concept "leave nothing behind" is proposed, and some novel treatment methods and devices, such as paclitaxel-coated balloon dilation, directional atherectomy, are developed. Directional atherectomy can effectively remove the atherosclerosis plaque but leave the inflammatory reaction along the atherectomy route. Here, we propose the hypothesis that using local drug delivery with balloon system can relieve the inflammation induced by atherectomy. Therefore, 40 patients of femoropopliteal occlusive disease will be randomly allocated into the group "directional atherectomy+local drug delivery with balloon system" or "drug-coated balloon only". The 1-year patency rate, incidence of complications, imaging parameters will be compared between groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

only the doctor know the group the patient goes into

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age of 18-80 years old
  • patients of femoropopliteal occlusive disease (Rutherford 2-4)
  • length of lesion ≤ 20cm
  • have signed the informed consent

排除标准

  • serum Cr > 150 umol/L
  • patients with acute thrombosis
  • received endovascular treatment for femoropopliteal disease in recent 6 months
  • less than 1 run-off vessel
  • allergic to aspirin, heparin, clopidogrel, paclitaxel, contrast medium
  • pregnancy and lactation
  • relatively easy bleeding
  • malignancy or irreversible organ failure

结局指标

主要结局

patency rate

时间窗: 12 months

the rate of patency of target vessel

late lumen loss rate

时间窗: 12 months

the rate of late lumen loss of target vessel

次要结局

  • incidence of complications(12 months)
  • adverse events(12 months)
  • Rutherford level(12 months)
  • re-stenosis rate(12 months)
  • ABI(12 months)
  • main amputation(12 months)
  • MLD(12 months)
  • clinical outcomes(12 months)

研究者

申办方类型
Other
责任方
Sponsor

相似试验